1. Home
  2. Products
  3. Customized ADCs
  4. TACSTD2
  5. Anti-TACSTD2 (clone C16)-Mc-VC-MMAD ADC

Anti-TACSTD2 (clone C16)-Mc-VC-MMAD ADC (CAT#: ADC-W-570)

This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone C16) conjugated via a Mc-VC linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAD binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • C16
  • Name
  • TACSTD2
  • Alternative Names
  • TACSTD2; tumor-associated calcium signal transducer 2; EGP1; GP50; M1S1; EGP-1; TROP2; GA7331; GA733-1; epithelial glycoprotein-1; cell surface glycoprotein TROP2; cell surface glycoprotein Trop-2; pancreatic carcinoma marker protein GA7331; pancreatic ca
  • Target Entrez Gene ID
  • 4070
  • Overview
  • This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals. Mutations of this gene have been associated with gelatinous drop-like corneal dystrophy.
  • Overview
  • Anti-TACSTD2 Antibody, clone # C16
  • Clone #
  • C16
  • Species Reactivity
  • Human
  • Name
  • Mc-VC (maleimidocaproyl-valine-alanine)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
  • Name
  • MMAD (monomethyl auristatin D)
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-570. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-292 Anti-TACSTD2 (clone 7E6)-PEG6-MMAD ADC PEG6 ((Propylene Glycol)-6-propionyl) MMAD (monomethyl auristatin D)
ADC-W-538 Anti-TACSTD2 (clone C16)-PEG6-MMAD ADC Amino-PEG6-based linker MMAD (monomethyl auristatin D)
ADC-W-290 Anti-TACSTD2 (clone 7E6)-AcLys-VC-PABC-MMAD ADC AcLys-VC- PABC (Acetyl-lysine-valine-citrulline-p-aminobenzyloxycarbonyl) MMAD (monomethyl auristatin D)
ADC-W-563 Anti-TACSTD2 (clone C16)-VC-PABC-Aur0101 ADC VC-PABC (valine-citrulline-p-aminobenzylcarbamate) Aur0101
ADC-W-568 Anti-TACSTD2 (clone C16)-VC-MMAD ADC VC (valine-citrulline) MMAD (monomethyl auristatin D)
CAT# Product Name Linker Payload
ADC-W-492 Anti-CD33 (h2H12ec)-Mc-VC-SGD-1882 ADC mc-VC (maleimidocaproyl-valine-alanine) SGD-1882
CAT# Product Name Linker Payload
ADC-W-413 Anti-ERBB2 (Trastuzumab)-hydroxyl amino PEG linker-MMAD (monomethyl auristatin D) ADC hydroxyl amino PEG linker MMAD (monomethyl auristatin D)
ADC-W-408 Anti-ERBB2 (Trastuzumab)-MMAD ADC Non-Cleavable hydroxyl amino PEG linker MMAD (monomethyl auristatin D)
ADC-W-167 Anti-TPBG (L443C)-VC-MMAD ADC VC (valine-citrulline) MMAD (monomethyl auristatin D)
ADC-W-292 Anti-TACSTD2 (clone 7E6)-PEG6-MMAD ADC PEG6 ((Propylene Glycol)-6-propionyl) MMAD (monomethyl auristatin D)
ADC-W-312 Anti-TPBG (clone A1)-hydroxyl amino PEG-MMAD ADC hydroxyl amino PEG linker MMAD (monomethyl auristatin D)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.